4 completed, 1 recruiting. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 4, Recruiting 1 |
Follow Visual Impairment: new trials by email Literature Review of Visual Impairment trials Research Report on Visual Impairment
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy Faricimab, fluocinolone acetonide - Radiation Retinopathy, Visual Impairment | Phase 3 | Recruiting | Jaeb Center for Health Research | 600 | 2023-11-21 | 2026-10-23 |
| mHealth Intervention for Improving Eye Health at Community Level Screening program including 2 consecutive tests, Screening program with mobile health - Visual Impairment | Phase 3 | Completed | Shahid Beheshti University of Medical Sciences | 3300 | 2017-04-15 | 2019-04-23 |
| A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients Ranibizumab (RFB002), Laser, Sham injection - Diabetic Macular Edema, Visual Impairment | Phase 3 | Completed | Novartis Pharmaceuticals | 384 | 2014-11-05 | 2019-02-01 |
| Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO) Ranibizumab, Dexamethasone implant and sham injections - Visual Impairment, Macular Edema | Phase 3 | Completed | Novartis Pharmaceuticals | 243 | 2011-08-01 | 2016-09-27 |
| Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO) Ranibizumab, Dexamethasone Implant, Sham injection - Visual Impairment, Macular Edema | Phase 3 | Completed | Novartis Pharmaceuticals | 244 | 2011-07-01 | 2014-08-07 |
Vision Disorders (5) · Macular Edema (3) · Retinal Vein Occlusion (2) · Diabetes Mellitus (1)
Eye Diseases (5) · Nervous System Diseases (5) · Neurologic Manifestations (5) · Pathological Conditions, Signs and Symptoms (5) · Sensation Disorders (5) · Signs and Symptoms (5) · Macular Degeneration (3) · Retinal Degeneration (3) · Retinal Diseases (3) · Cardiovascular Diseases (2) · Embolism and Thrombosis (2) · Thrombosis (2) · Vascular Diseases (2) · Venous Thrombosis (2) · Endocrine System Diseases (1)
Ranibizumab (3) · Dexamethasone (2) · salicylhydroxamic acid (2) · Fluocinolone Acetonide (1) · Lasers (1) · faricimab (1)
Novartis Pharmaceuticals (3) · Jaeb Center for Health Research (1) · Shahid Beheshti University of Medical Sciences (1)
Germany (2) · Hungary (2) · Poland (2) · United Kingdom (2) · China (1) · Czechia (1) · Iran (1) · United States (1)
UG1EY014231 (1)